© 2003 by Heart
JournalScan
JournalScan
| The first 150 words of the full text of this article appear below. |
Ischaemic heart disease
Invasive treatment of ACS is cost neutral
It is now clear that invasive treatment for acute coronary syndromes (ACS) is clinically effective in most patients. However, this entails the use of catheterisation facilities and additional consumables. This study suggests that the cost of the invasive strategy, including the use of tirofiban, is US$6100 v $7200 for the conservative strategy at six months (confidence interval of difference -$2000 to +$78). The cost-per-life-year gained with the invasive strategy was $12700 (range $8400$27800).
Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS, for the TACTICS-TIMI 18 Investigators. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:18518.
Aspirin restarted within 48 hours of bypass surgery saves lives
In
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
